NXGL
NEXGEL, Inc.
Medical - Instruments & Supplies
Market Cap$5M
5Y Perf.-77.3%
Compare Stocks
5 / 10Try these comparisons:
Stock Comparison
NXGL vs DBVT vs PRGO vs ALKS vs MCK
Revenue, margins, valuation, and 5-year total return — side by side.
DBVT
DBV Technologies S.A.
Biotechnology
Market Cap$1690.08T
5Y Perf.+23.3%
PRGO
Perrigo Company plc
Drug Manufacturers - Specialty & Generic
Market Cap$1.62B
5Y Perf.-69.9%
ALKS
Alkermes plc
Biotechnology
Market Cap$5.83B
5Y Perf.+50.4%
MCK
McKesson Corporation
Medical - Distribution
Market Cap$90.21B
5Y Perf.+196.3%
NXGL vs DBVT vs PRGO vs ALKS vs MCK — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | NXGL | DBVT | PRGO | ALKS | MCK |
|---|---|---|---|---|---|
| Industry | Medical - Instruments & Supplies | Biotechnology | Drug Manufacturers - Specialty & Generic | Biotechnology | Medical - Distribution |
| Market Cap | $5M | $1690.08T | $1.62B | $5.83B | $90.21B |
| Revenue (TTM) | $12M | $0.00 | $4.18B | $1.56B | $403.43B |
| Net Income (TTM) | $-3M | $-168M | $-1.82B | $153M | $4.76B |
| Gross Margin | 38.3% | — | 34.2% | 65.4% | 3.6% |
| Operating Margin | -25.5% | — | -4.1% | 12.3% | 1.5% |
| Forward P/E | — | — | 5.5x | 24.5x | 16.7x |
| Total Debt | $3M | $22M | $3.97B | $70M | $8.61B |
| Cash & Equiv. | $2M | $194M | $532M | $1.12B | $3.98B |
NXGL vs DBVT vs PRGO vs ALKS vs MCK — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
NXGL
DBVT
PRGO
ALKS
MCK
| Stock | Dec 21 | May 26 | Return |
|---|---|---|---|
| NEXGEL, Inc. (NXGL) | 100 | 22.7 | -77.3% |
| DBV Technologies S.… (DBVT) | 100 | 123.3 | +23.3% |
| Perrigo Company plc (PRGO) | 100 | 30.1 | -69.9% |
| Alkermes plc (ALKS) | 100 | 150.4 | +50.4% |
| McKesson Corporation (MCK) | 100 | 296.3 | +196.3% |
Price return only. Dividends and distributions are not included.
Quick Verdict: NXGL vs DBVT vs PRGO vs ALKS vs MCK
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: NXGL and PRGO are tied at the top with 2 categories each (5-stock set) — the right choice depends on your priorities. Perrigo Company plc is the stronger pick specifically for valuation and capital efficiency and dividend income and shareholder returns. DBVT, ALKS, and MCK also each lead in at least one category. As sector peers, any of these can serve as alternatives in the same allocation.
NXGL
NEXGEL, Inc.
The Growth Play
NXGL has the current edge in this matchup, primarily because of its strength in growth exposure.
- Rev growth 112.5%, EPS growth 10.7%, 3Y rev CAGR 77.6%
- 112.5% revenue growth vs DBVT's -100.0%
- Beta 0.85 vs DBVT's 1.26
Best for: growth exposure
DBVT
DBV Technologies S.A.
The Momentum Pick
DBVT ranks third and is worth considering specifically for momentum.
- +100.5% vs NXGL's -77.3%
Best for: momentum
PRGO
Perrigo Company plc
The Income Pick
PRGO is the #2 pick in this set and the best alternative if income & stability and defensive is your priority.
- Dividend streak 10 yrs, beta 1.21, yield 9.8%
- Beta 1.21, yield 9.8%, current ratio 2.76x
- Lower P/E (5.5x vs 16.7x)
- 9.8% yield, 10-year raise streak, vs MCK's 0.4%, (3 stocks pay no dividend)
Best for: income & stability and defensive
ALKS
Alkermes plc
The Defensive Pick
ALKS is the clearest fit if your priority is sleep-well-at-night.
- Lower volatility, beta 1.00, Low D/E 3.8%, current ratio 3.55x
- 9.8% margin vs PRGO's -43.5%
Best for: sleep-well-at-night
MCK
McKesson Corporation
The Long-Run Compounder
MCK is the clearest fit if your priority is long-term compounding.
- 339.0% 10Y total return vs ALKS's -12.0%
- 5.7% ROA vs DBVT's -89.0%
Best for: long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | NXGL | 112.5% revenue growth vs DBVT's -100.0% |
| Value | PRGO | Lower P/E (5.5x vs 16.7x) |
| Quality / Margins | ALKS | 9.8% margin vs PRGO's -43.5% |
| Stability / Safety | NXGL | Beta 0.85 vs DBVT's 1.26 |
| Dividends | PRGO | 9.8% yield, 10-year raise streak, vs MCK's 0.4%, (3 stocks pay no dividend) |
| Momentum (1Y) | DBVT | +100.5% vs NXGL's -77.3% |
| Efficiency (ROA) | MCK | 5.7% ROA vs DBVT's -89.0% |
NXGL vs DBVT vs PRGO vs ALKS vs MCK — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2024
Segment breakdown not available.
FY 2025
FY 2025
FY 2026
NXGL vs DBVT vs PRGO vs ALKS vs MCK — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLMCKLAGGINGDBVT
Who Leads Where
MCK leads in 2 of 6 categories
ALKS leads 1 • PRGO leads 1 • NXGL leads 0 • DBVT leads 0 • 2 tied
Explore the data ↓DBVTDBV Technologies S.A.
0leads
NXGLNEXGEL, Inc.
0leads
ALKSAlkermes plc
1leads
PRGOPerrigo Company plc
1leads
MCKMcKesson Corporation
2leads
6 Total Categories
CATEGORYLEADERvs PRGOvs ALKSMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
ALKS5/6
Valuation MetricsMultiples, price ratios, and targets
PRGO4/6
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
MCK6/9
Total Returns1Y, 3Y, 5Y total returns with dividends
MCK4/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
Tied
—
Income & Cash Flow (Last 12 Months)
ALKS leads this category, winning 5 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
MCK and DBVT operate at a comparable scale, with $403.4B and $0 in trailing revenue. ALKS is the more profitable business, keeping 9.8% of every revenue dollar as net income compared to PRGO's -43.5%. On growth, ALKS holds the edge at +28.2% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | NXGLNEXGEL, Inc. | DBVTDBV Technologies … | PRGOPerrigo Company p… | ALKSAlkermes plc | MCKMcKesson Corporat… |
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $12M | $0 | $4.2B | $1.6B | $403.4B |
| EBITDAEarnings before interest/tax | -$2M | -$112M | $58M | $212M | $6.8B |
| Net IncomeAfter-tax profit | -$3M | -$168M | -$1.8B | $153M | $4.8B |
| Free Cash FlowCash after capex | -$3M | -$151M | $108M | $392M | $6.0B |
| Gross MarginGross profit ÷ Revenue | +38.3% | — | +34.2% | +65.4% | +3.6% |
| Operating MarginEBIT ÷ Revenue | -25.5% | — | -4.1% | +12.3% | +1.5% |
| Net MarginNet income ÷ Revenue | -24.7% | — | -43.5% | +9.8% | +1.2% |
| FCF MarginFCF ÷ Revenue | -21.8% | — | +2.6% | +25.1% | +1.5% |
| Rev. Growth (YoY)Latest quarter vs prior year | -0.2% | — | -7.2% | +28.2% | +6.0% |
| EPS Growth (YoY)Latest quarter vs prior year | +27.3% | +91.5% | -56.4% | -4.1% | +37.0% |
ALKS leads this category, winning 5 of 6 comparable metrics.
Valuation Metrics
PRGO leads this category, winning 4 of 6 comparable metrics.
Valuation Metrics
At 19.2x trailing earnings, MCK trades at a 22% valuation discount to ALKS's 24.5x P/E. On an enterprise value basis, PRGO's 7.4x EV/EBITDA is more attractive than ALKS's 17.0x.
| Metric | NXGLNEXGEL, Inc. | DBVTDBV Technologies … | PRGOPerrigo Company p… | ALKSAlkermes plc | MCKMcKesson Corporat… |
|---|---|---|---|---|---|
| Market CapShares × price | $5M | $1690.08T | $1.6B | $5.8B | $90.2B |
| Enterprise ValueMkt cap + debt − cash | $6M | $1690.08T | $5.1B | $4.8B | $94.9B |
| Trailing P/EPrice ÷ TTM EPS | -1.19x | -0.75x | -1.14x | 24.47x | 19.19x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — | 5.53x | — | 16.66x |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — | 0.43x |
| EV / EBITDAEnterprise value multiple | — | — | 7.43x | 17.01x | 15.27x |
| Price / SalesMarket cap ÷ Revenue | 0.56x | — | 0.38x | 3.95x | 0.22x |
| Price / BookPrice ÷ Book value/share | 0.64x | 0.65x | 0.55x | 3.25x | 11.63x |
| Price / FCFMarket cap ÷ FCF | — | — | 11.17x | 12.14x | 14.66x |
PRGO leads this category, winning 4 of 6 comparable metrics.
Profitability & Efficiency
MCK leads this category, winning 6 of 9 comparable metrics.
Profitability & Efficiency
MCK delivers a 3.0% return on equity — every $100 of shareholder capital generates $3 in annual profit, vs $-130 for DBVT. ALKS carries lower financial leverage with a 0.04x debt-to-equity ratio, signaling a more conservative balance sheet compared to PRGO's 1.35x. On the Piotroski fundamental quality scale (0–9), ALKS scores 7/9 vs PRGO's 4/9, reflecting strong financial health.
| Metric | NXGLNEXGEL, Inc. | DBVTDBV Technologies … | PRGOPerrigo Company p… | ALKSAlkermes plc | MCKMcKesson Corporat… |
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | -51.7% | -130.2% | -50.7% | +8.8% | +3.0% |
| ROA (TTM)Return on assets | -26.9% | -89.0% | -19.8% | +5.4% | +5.7% |
| ROICReturn on invested capital | -43.1% | — | +3.7% | +18.9% | +74.5% |
| ROCEReturn on capital employed | -44.7% | -145.7% | +4.3% | +14.2% | +43.1% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 4 | 4 | 7 | 7 |
| Debt / EquityFinancial leverage | 0.46x | 0.13x | 1.35x | 0.04x | 1.10x |
| Net DebtTotal debt minus cash | $1M | -$172M | $3.4B | -$1.0B | $4.6B |
| Cash & Equiv.Liquid assets | $2M | $194M | $532M | $1.1B | $4.0B |
| Total DebtShort + long-term debt | $3M | $22M | $4.0B | $70M | $8.6B |
| Interest CoverageEBIT ÷ Interest expense | -40.04x | -189.82x | -7.20x | 32.30x | 33.79x |
MCK leads this category, winning 6 of 9 comparable metrics.
Total Returns (Dividends Reinvested)
MCK leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in MCK five years ago would be worth $37,043 today (with dividends reinvested), compared to $1,685 for NXGL. Over the past 12 months, DBVT leads with a +100.5% total return vs NXGL's -77.3%. The 3-year compound annual growth rate (CAGR) favors MCK at 26.4% vs NXGL's -26.3% — a key indicator of consistent wealth creation.
| Metric | NXGLNEXGEL, Inc. | DBVTDBV Technologies … | PRGOPerrigo Company p… | ALKSAlkermes plc | MCKMcKesson Corporat… |
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | -67.2% | +3.6% | -13.6% | +23.8% | -10.5% |
| 1-Year ReturnPast 12 months | -77.3% | +100.5% | -52.0% | +15.2% | +7.2% |
| 3-Year ReturnCumulative with dividends | -59.9% | +18.1% | -58.1% | +13.2% | +102.1% |
| 5-Year ReturnCumulative with dividends | -83.1% | -68.3% | -60.3% | +61.7% | +270.4% |
| 10-Year ReturnCumulative with dividends | -83.1% | -87.1% | -77.7% | -12.0% | +339.0% |
| CAGR (3Y)Annualised 3-year return | -26.3% | +5.7% | -25.2% | +4.2% | +26.4% |
MCK leads this category, winning 4 of 6 comparable metrics.
Risk & Volatility
Evenly matched — ALKS and MCK each lead in 1 of 2 comparable metrics.
Risk & Volatility
MCK is the less volatile stock with a -0.02 beta — it tends to amplify market swings less than DBVT's 1.26 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ALKS currently trades 95.6% from its 52-week high vs NXGL's 20.0% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | NXGLNEXGEL, Inc. | DBVTDBV Technologies … | PRGOPerrigo Company p… | ALKSAlkermes plc | MCKMcKesson Corporat… |
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.85x | 1.26x | 1.21x | 1.00x | -0.02x |
| 52-Week HighHighest price in past year | $2.97 | $26.18 | $28.44 | $36.60 | $999.00 |
| 52-Week LowLowest price in past year | $0.56 | $7.53 | $9.23 | $25.17 | $637.00 |
| % of 52W HighCurrent price vs 52-week peak | +20.0% | +75.3% | +41.2% | +95.6% | +73.7% |
| RSI (14)Momentum oscillator 0–100 | 45.1 | 47.4 | 53.1 | 60.5 | 21.0 |
| Avg Volume (50D)Average daily shares traded | 371K | 252K | 3.3M | 2.2M | 782K |
Evenly matched — ALKS and MCK each lead in 1 of 2 comparable metrics.
Analyst Outlook
Evenly matched — PRGO and MCK each lead in 1 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: DBVT as "Buy", PRGO as "Hold", ALKS as "Buy", MCK as "Buy". Consensus price targets imply 209.1% upside for PRGO (target: $36) vs 31.5% for ALKS (target: $46). For income investors, PRGO offers the higher dividend yield at 9.82% vs MCK's 0.42%.
| Metric | NXGLNEXGEL, Inc. | DBVTDBV Technologies … | PRGOPerrigo Company p… | ALKSAlkermes plc | MCKMcKesson Corporat… |
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy | Hold | Buy | Buy |
| Price TargetConsensus 12-month target | — | $46.33 | $36.20 | $46.00 | $994.86 |
| # AnalystsCovering analysts | — | 15 | 36 | 28 | 31 |
| Dividend YieldAnnual dividend ÷ price | — | — | +9.8% | — | +0.4% |
| Dividend StreakConsecutive years of raises | — | 0 | 10 | 0 | 18 |
| Dividend / ShareAnnual DPS | — | — | $1.15 | — | $3.07 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | 0.0% | +0.5% | 0.0% |
Evenly matched — PRGO and MCK each lead in 1 of 2 comparable metrics.
Key Takeaway
MCK leads in 2 of 6 categories (Profitability & Efficiency, Total Returns). ALKS leads in 1 (Income & Cash Flow). 2 tied.
Best OverallMcKesson Corporation (MCK)Leads 2 of 6 categories
Loading custom metrics...
NXGL vs DBVT vs PRGO vs ALKS vs MCK: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is NXGL or DBVT or PRGO or ALKS or MCK a better buy right now?
For growth investors, NEXGEL, Inc.
(NXGL) is the stronger pick with 112. 5% revenue growth year-over-year, versus -5. 2% for Alkermes plc (ALKS). McKesson Corporation (MCK) offers the better valuation at 19. 2x trailing P/E (16. 7x forward), making it the more compelling value choice. Analysts rate DBV Technologies S. A. (DBVT) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — NXGL or DBVT or PRGO or ALKS or MCK?
On trailing P/E, McKesson Corporation (MCK) is the cheapest at 19.
2x versus Alkermes plc at 24. 5x. On forward P/E, Perrigo Company plc is actually cheaper at 5. 5x — notably different from the trailing picture, reflecting expected earnings growth.
03Which is the better long-term investment — NXGL or DBVT or PRGO or ALKS or MCK?
Over the past 5 years, McKesson Corporation (MCK) delivered a total return of +270.
4%, compared to -83. 1% for NEXGEL, Inc. (NXGL). Over 10 years, the gap is even starker: MCK returned +339. 0% versus DBVT's -87. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — NXGL or DBVT or PRGO or ALKS or MCK?
By beta (market sensitivity over 5 years), McKesson Corporation (MCK) is the lower-risk stock at -0.
02β versus DBV Technologies S. A. 's 1. 26β — meaning DBVT is approximately -7786% more volatile than MCK relative to the S&P 500. On balance sheet safety, Alkermes plc (ALKS) carries a lower debt/equity ratio of 4% versus 135% for Perrigo Company plc — giving it more financial flexibility in a downturn.
05Which is growing faster — NXGL or DBVT or PRGO or ALKS or MCK?
By revenue growth (latest reported year), NEXGEL, Inc.
(NXGL) is pulling ahead at 112. 5% versus -5. 2% for Alkermes plc (ALKS). On earnings-per-share growth, the picture is similar: McKesson Corporation grew EPS 49. 2% year-over-year, compared to -723. 2% for Perrigo Company plc. Over a 3-year CAGR, NXGL leads at 77. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — NXGL or DBVT or PRGO or ALKS or MCK?
Alkermes plc (ALKS) is the more profitable company, earning 16.
4% net margin versus -37. 8% for NEXGEL, Inc. — meaning it keeps 16. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ALKS leads at 17. 2% versus -40. 9% for NXGL. At the gross margin level — before operating expenses — ALKS leads at 86. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is NXGL or DBVT or PRGO or ALKS or MCK more undervalued right now?
On forward earnings alone, Perrigo Company plc (PRGO) trades at 5.
5x forward P/E versus 16. 7x for McKesson Corporation — 11. 1x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for PRGO: 209. 1% to $36. 20.
08Which pays a better dividend — NXGL or DBVT or PRGO or ALKS or MCK?
In this comparison, PRGO (9.
8% yield), MCK (0. 4% yield) pay a dividend. NXGL, DBVT, ALKS do not pay a meaningful dividend and should not be held primarily for income.
09Is NXGL or DBVT or PRGO or ALKS or MCK better for a retirement portfolio?
For long-horizon retirement investors, McKesson Corporation (MCK) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0.
02), +339. 0% 10Y return). Both have compounded well over 10 years (MCK: +339. 0%, DBVT: -87. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between NXGL and DBVT and PRGO and ALKS and MCK?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: NXGL is a small-cap high-growth stock; DBVT is a mega-cap quality compounder stock; PRGO is a small-cap income-oriented stock; ALKS is a small-cap quality compounder stock; MCK is a mid-cap quality compounder stock. PRGO pays a dividend while NXGL, DBVT, ALKS, MCK do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.